<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059668</url>
  </required_header>
  <id_info>
    <org_study_id>STR- HNprädBio-2013</org_study_id>
    <nct_id>NCT02059668</nct_id>
  </id_info>
  <brief_title>Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)</brief_title>
  <acronym>HNprädBio</acronym>
  <official_title>Observational Study on Biomarkers in Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical research project is to validate the prognostic impact of potential&#xD;
      biomarkers on loco-regional control of locally advanced head and neck cancer after definitive&#xD;
      or adjuvant radiochemotherapy. The treatment is equal to the standard of care.&#xD;
&#xD;
      Potential biomarkers from a previous retrospective study will be validated in this&#xD;
      prospective study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary: Evaluation of local-regional recurrence- free survival after two years of patients&#xD;
      with locally advanced head and neck cancer who received definitive or adjuvant&#xD;
      radiochemotherapy.&#xD;
&#xD;
      Secondary: Evaluation of disease-free -survival, metastases-free and overall survival after&#xD;
      two years, of patients with locally advanced head and neck cancer.&#xD;
&#xD;
      Outline: This is a multicenter observational study. The treatment is based on the center&#xD;
      specific standard of care. The total dose will be between 69 and 73 Gy (definitive treatment)&#xD;
      and 63 and 66 Gy (adjuvant treatment), the chemotherapy will be cisplatin- based.&#xD;
&#xD;
      The aim of the analysis is to validate the prognostic impact of potential biomarkers on&#xD;
      loco-regional control. This will lead to the definition of risk groups and stratification of&#xD;
      patients and will help to individualize radiotherapy prescription in future trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>local recurrence free survival</measure>
    <time_frame>after 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metastases-free survival</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Biomarker analyses head &amp; neck cancer tissue, blood specimen</arm_group_label>
    <description>Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biomarker analyses head &amp; neck cancer tissue, blood specimen</intervention_name>
    <description>For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.</description>
    <arm_group_label>Biomarker analyses head &amp; neck cancer tissue, blood specimen</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      if possible fresh-frozen tumor tissues, blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the diagnosis locally advanced squamous cell carcinoma of the head and neck&#xD;
        area&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Primary radiochemotherapy:&#xD;
&#xD;
          -  Patients with locally advanced squamous cell carcinoma of the oral cavity, oropharynx&#xD;
             or hypopharynx&#xD;
&#xD;
          -  Stage III or IV without distant metastases&#xD;
&#xD;
          -  Patient is able to participate in regular tumor follow-up care&#xD;
&#xD;
          -  planned irradiation dose 69-72 Gy&#xD;
&#xD;
          -  planned overall treatment time 38-54 days&#xD;
&#xD;
          -  written informed consent of the patient&#xD;
&#xD;
          -  general condition according to WHO 0-2&#xD;
&#xD;
          -  planned simultaneous chemotherapy with cisplatin (cumulative planned total dose&#xD;
             minimum 180 mg/m2 body surface, divided in several separately doses)&#xD;
&#xD;
        Adjuvant radiochemotherapy:&#xD;
&#xD;
          -  Patients with locally advanced squamous cell carcinoma of the oral cavity, oropharynx&#xD;
             or hypopharynx&#xD;
&#xD;
          -  surgery, existence of one or more of the following risk factors for local recurrence:&#xD;
&#xD;
          -  extracapsular growth of a minimum of one lymph node metastasis&#xD;
&#xD;
          -  R1 resection&#xD;
&#xD;
          -  pT4 tumor and more than 3 affected lymph nodes&#xD;
&#xD;
          -  Patient is able to participate in regular tumor follow-up care&#xD;
&#xD;
          -  planned irradiation dose 63-66 Gy&#xD;
&#xD;
          -  planned overall treatment time 44-48 days&#xD;
&#xD;
          -  planned simultaneous chemotherapy with cisplatin (cumulative planned total dose&#xD;
             minimum 200 mg/m2 body surface, divided in several separately doses)&#xD;
&#xD;
          -  written informed consent of the patient&#xD;
&#xD;
          -  general condition according to WHO 0-2&#xD;
&#xD;
          -  time since last surgery &lt;56 days (8 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Primary radiochemotherapy:&#xD;
&#xD;
          -  distant metastasis&#xD;
&#xD;
          -  contraindication against a cisplatin-based chemotherapy&#xD;
&#xD;
          -  planned total irradiation dose &lt;69 Gy and &gt;72 Gy&#xD;
&#xD;
          -  planned overall treatment time &gt;54 days or &lt;38 days&#xD;
&#xD;
          -  Patient is incapable of giving consent&#xD;
&#xD;
          -  previous radiotherapy in the head and neck area, if there is a risk for overlapping of&#xD;
             the irradiation areas&#xD;
&#xD;
          -  other tumor diseases, which currently need a treatment or probably within the next two&#xD;
             years or which influence the prognosis of the patient&#xD;
&#xD;
          -  tumor-independent diseases or conditions which reduce the survival probability of the&#xD;
             patient to &lt;2 years or which affect the follow-up over 2 years&#xD;
&#xD;
          -  no written informed consent&#xD;
&#xD;
          -  induction chemotherapy&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
        Adjuvant radiochemotherapy:&#xD;
&#xD;
          -  distant metastasis&#xD;
&#xD;
          -  contraindication against a cisplatin-based chemotherapy&#xD;
&#xD;
          -  planned total irradiation dose &lt; 63 Gy or &gt; 66 Gy&#xD;
&#xD;
          -  planned overall treatment time &gt; 48 days or &lt; 44 day&#xD;
&#xD;
          -  Patient is incapable of giving consent&#xD;
&#xD;
          -  previous radiotherapy in the head and neck area, if there is a risk for overlapping of&#xD;
             the irradiation areas&#xD;
&#xD;
          -  other tumor diseases, which currently need a treatment or probably within the next two&#xD;
             years or which influence the prognosis of the patient&#xD;
&#xD;
          -  tumor-independent diseases or conditions which reduce the survival probability of the&#xD;
             patient to &lt;2 years or which affect the follow-up over 2 years&#xD;
&#xD;
          -  no written informed consent&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dresden University of Technology, Universital Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prof. Anca-Ligia Grosu</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca-Ligia Grosu, Prof.</last_name>
      <phone>+49 761 270 94610</phone>
      <email>anca.grosu@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Ana-Ligia Grosu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Jürgen Debus</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Debus, Prof.</last_name>
      <phone>+49 6221 / 56 82 01</phone>
      <email>Juergen.Debus@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Debus, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Daniel Zips</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zips, Prof.</last_name>
      <phone>+49 7071/29-8 21 65</phone>
      <email>ROInfo@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Zips, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Claus Belka</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Belka, Prof.</last_name>
      <phone>+49 89 7095 4520</phone>
      <email>Claus.Belka@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Claus Belka, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Stephanie Combs</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Combs, Prof.</last_name>
      <phone>+49 89 41 40-45 02</phone>
      <email>radonk@lrz.tum.de</email>
    </contact>
    <investigator>
      <last_name>Stephanie Combs, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Claus Rödel</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Rödel, Prof.</last_name>
      <phone>+ 49 69 / 6301-5130</phone>
      <email>strahlentherapie@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Claus Rödel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Martin Stuschke</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Stuschke, Prof.</last_name>
      <phone>+49 201 / 723-23 20</phone>
      <email>martin.stuschke@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Stuschke, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Mechthild Krause</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mechthild Krause, Prof.</last_name>
      <phone>+49 351 458 2238</phone>
      <email>studien.str@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Mechthild Krause, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Volker Budach</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Budach, Prof.</last_name>
      <phone>+49 30 450 527 152</phone>
    </contact>
    <investigator>
      <last_name>Volker Budach, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie im Krankenhaus Dresden - Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schreiber Andreas, Dr.</last_name>
      <email>strahlentherapie@khdf.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Prof. Dr. Mechthild Krause</investigator_title>
  </responsible_party>
  <keyword>locally advanced head and neck cancer</keyword>
  <keyword>biomarkers</keyword>
  <keyword>definitive treatment</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

